SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nexentis Says MitoCareX Completes Initial Computational Drug Screening

Nexentis said MitoCareX completed an initial computational screening stage with Boltz. The company described the findings as preliminary and not experimentally validated, but encouraging for further analysis and experimental investigation.

NXTS

Related stories